The Technical Analyst
Zymeworks Inc [ZYME]
Exchange: NYSE Sector: Healthcare Industry: Biotechnology
Zymeworks Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.04% $9.25
America/New_York / 9 mai 2024 @ 11:53
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 653.67 mill |
| EPS: | -1.780 |
| P/E: | -5.19 |
| Earnings Date: | Aug 08, 2024 |
| SharesOutstanding: | 70.70 mill |
| Avg Daily Volume: | 0.614 mill |
| RATING 2024-05-08 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.19 | sector: PE 15.43 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.13x |
| Company: PE -5.19 | industry: PE 40.47 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-8.96 (-196.88%) $-18.20 |
| Date: 2024-05-09 |
| Expected Trading Range (DAY) |
|---|
|
$ 8.81 - 9.63 ( +/- 4.49%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-02 | Gallagher Neil | Buy | 74 000 | Stock Option (Right to Buy) |
| 2024-04-02 | Gallagher Neil | Sell | 0 | No securities are beneficially owned |
| 2024-02-22 | Platshon Scott | Buy | 0 | |
| 2024-02-08 | Cesano Alessandra | Buy | 74 000 | Stock Option (Right to Buy) |
| 2024-02-08 | Cesano Alessandra | Sell | 0 | No securities are beneficially owned |
| INSIDER POWER |
|---|
| 94.04 |
| Last 71 transactions |
| Buy: 13 173 358 | Sell: 322 010 |
Forecast:
13:33 - $9.29
Live Trading Signals (every 1 min)
Forecast
1: 12:03 - $9.24
Forecast 2: 12:53 - $9.24
Forecast 3: 13:33 - $9.29
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $9.25 (2.04% ) |
| Volume | 0.135 mill |
| Avg. Vol. | 0.614 mill |
| % of Avg. Vol | 22.03 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ZYME
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ZYME
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Latest Press Releases
2024-05-08 22:30:00 - Press Release
Shareholders That Lost Money On Zymeworks Inc.(zyme) Should Contact Levi & Korsinsky About Securities Fraud Investigation - Zyme
New york, ny / accesswire / may 8, 2024 / levi & korsinsky notifies investors that it has commenced an investigation of zymeworks inc. ("zymeworks") (nasdaq:zyme) concerning possible violations of federal securities laws. zymeworks disclosed, on april 1, 2024, that it had removed christopher astle ("astle") from the positions of senior vice president ("svp") and chief financial officer ("cfo"), effective immediately.
2024-05-08 07:22:00 - Press Release
Shareholder Rights Advocates At Levi & Korsinsky Investigate Zymeworks Inc. (zyme) Regarding Possible Securities Fraud Violations
New york, ny / accesswire / may 8, 2024 / levi & korsinsky notifies investors that it has commenced an investigation of zymeworks inc. ("zymeworks") (nasdaq:zyme) concerning possible violations of federal securities laws. zymeworks disclosed, on april 1, 2024, that it had removed christopher astle ("astle") from the positions of senior vice president ("svp") and chief financial officer ("cfo"), effective immediately.
2024-05-06 20:30:00 - Press Release
Attention Zymeworks Inc. Investors: You May Have Been Affected By Fraud- Contact Levi & Korsinsky To Discuss Your Rights
New york, ny / accesswire / may 6, 2024 / levi & korsinsky notifies investors that it has commenced an investigation of zymeworks inc. ("zymeworks") (nasdaq:zyme) concerning possible violations of federal securities laws. zymeworks disclosed, on april 1, 2024, that it had removed christopher astle ("astle") from the positions of senior vice president ("svp") and chief financial officer ("cfo"), effective immediately.
2024-05-06 19:38:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Zymeworks Inc. - Zyme
New york , may 6, 2024 /prnewswire/ -- pomerantz llp is investigating claims on behalf of investors of zymeworks inc. ("zymeworks" or the "company") (nasdaq: zyme). such investors are advised to contact danielle peyton at newaction@pomlaw.com or 646-581-9980, ext.
2024-05-06 07:40:00 - Press Release
Zymeworks Inc. Investigation Ongoing: Contact Levi & Korsinsky To Discuss Your Rights - Zyme
New york, ny / accesswire / may 6, 2024 / levi & korsinsky notifies investors that it has commenced an investigation of zymeworks inc. ("zymeworks") (nasdaq:zyme) concerning possible violations of federal securities laws. zymeworks disclosed, on april 1, 2024, that it had removed christopher astle ("astle") from the positions of senior vice president ("svp") and chief financial officer ("cfo"), effective immediately.
Latest News
2024-05-02 20:04:10 - Seeking Alpha
Zymeworks Inc. (ZYME) Q1 2024 Earnings Call Transcript
Zymeworks Inc. (NASDAQ:ZYME ) Q1 2024 Earnings Call Transcript May 2, 2024 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Ken Galbraith - Chair and CEO Paul Moore - Chief Scientific Officer Conference Call Participants Stephen Willey - Stifel Ashiq Mubarack - city Ivy Wang - Jefferies Brian Cheng - JPMorgan Jon Miller - Evercore ISI Operator Thank you for standing by. This is the conference operator.
2024-05-02 19:41:04 - Zacks Investment Research
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.37 per share a year ago.
2024-04-30 06:00:00 - GlobeNewsWire
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, April 30, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:
2024-04-25 08:01:19 - Zacks Investment Research
3 Top Stocks to Invest in for Amazing Earnings Acceleration
Invest in companies such as Zymeworks (ZYME), Evolus (EOLS) and Bilibili (BILI) for superb earnings acceleration.
2024-04-18 15:06:45 - Seeking Alpha
Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data
Zymeworks is a biotechnology company that develops innovative therapies for difficult-to-treat cancers and serious conditions. The company's flagship drug, Zanidatamab, is in phase 3 clinical trials and has significant market potential for biliary tract cancer. Zymeworks utilizes proprietary platforms to create multispecific antibody therapeutics and antibody-drug conjugate technologies for its drug candidates.
2024-04-11 06:00:00 - GlobeNewsWire
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its first quarter 2024 financial results after market close on May 2, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 2, 2024 at 4:30 pm Eastern Time (ET).
2024-04-10 10:36:05 - Zacks Investment Research
Zymeworks (ZYME) Loses -13.41% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zymeworks (ZYME) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
2024-03-27 06:00:00 - GlobeNewsWire
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:
2024-03-22 13:01:11 - Zacks Investment Research
Zymeworks (ZYME) Upgraded to Buy: What Does It Mean for the Stock?
Zymeworks (ZYME) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2024-03-08 10:18:15 - InvestorPlace
Next-Gen Winners: 7 Tech Stocks Set to Dominate the Decade
In the stock markets, fortunes rise and fall on the tide of hype and advancements, with the tech sector impacted the most. As the world is in the middle of a decade, the stage is set for the listed tech titans to emerge as veritable champions.